Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

N-(1-Phenylethyl)aziridine-2-carboxylate esters in the synthesis of biologically relevant compounds.

Głowacka IE, Trocha A, Wróblewski AE, Piotrowska DG.

Beilstein J Org Chem. 2019 Jul 23;15:1722-1757. doi: 10.3762/bjoc.15.168. eCollection 2019. Review.

2.

Wundversorgung des diabetischen Fußes.

Trocha AK.

Dtsch Med Wochenschr. 2017 Jul;142(13):1000-1006. doi: 10.1055/s-0043-106397. Epub 2017 Jul 3. German. No abstract available.

PMID:
28672422
3.

A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.

Jones RB, Mueller S, O'Connor R, Rimpel K, Sloan DD, Karel D, Wong HC, Jeng EK, Thomas AS, Whitney JB, Lim SY, Kovacs C, Benko E, Karandish S, Huang SH, Buzon MJ, Lichterfeld M, Irrinki A, Murry JP, Tsai A, Yu H, Geleziunas R, Trocha A, Ostrowski MA, Irvine DJ, Walker BD.

PLoS Pathog. 2016 Apr 15;12(4):e1005545. doi: 10.1371/journal.ppat.1005545. eCollection 2016 Apr.

4.

Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers.

Kikuchi T, Iwabu Y, Tada T, Kawana-Tachikawa A, Koga M, Hosoya N, Nomura S, Brumme ZL, Jessen H, Pereyra F, Trocha A, Walker BD, Iwamoto A, Tokunaga K, Miura T.

J Virol. 2015 May;89(9):4992-5001. doi: 10.1128/JVI.03464-14. Epub 2015 Feb 25.

5.

Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes.

Jones RB, O'Connor R, Mueller S, Foley M, Szeto GL, Karel D, Lichterfeld M, Kovacs C, Ostrowski MA, Trocha A, Irvine DJ, Walker BD.

PLoS Pathog. 2014 Aug 14;10(8):e1004287. doi: 10.1371/journal.ppat.1004287. eCollection 2014 Aug.

6.

Reduced replication capacity of NL4-3 recombinant viruses encoding reverse transcriptase-integrase sequences from HIV-1 elite controllers.

Brumme ZL, Li C, Miura T, Sela J, Rosato PC, Brumme CJ, Markle TJ, Martin E, Block BL, Trocha A, Kadie CM, Allen TM, Pereyra F, Heckerman D, Walker BD, Brockman MA.

J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):100-8. doi: 10.1097/QAI.0b013e3181fe9450.

7.

Impaired replication capacity of acute/early viruses in persons who become HIV controllers.

Miura T, Brumme ZL, Brockman MA, Rosato P, Sela J, Brumme CJ, Pereyra F, Kaufmann DE, Trocha A, Block BL, Daar ES, Connick E, Jessen H, Kelleher AD, Rosenberg E, Markowitz M, Schafer K, Vaida F, Iwamoto A, Little S, Walker BD.

J Virol. 2010 Aug;84(15):7581-91. doi: 10.1128/JVI.00286-10. Epub 2010 May 26.

8.

HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers.

Miura T, Brumme CJ, Brockman MA, Brumme ZL, Pereyra F, Block BL, Trocha A, John M, Mallal S, Harrigan PR, Walker BD.

J Virol. 2009 Apr;83(7):3407-12. doi: 10.1128/JVI.02459-08. Epub 2009 Jan 19. Erratum in: J Virol. 2010 Jan;84(2):1212.

9.

HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition.

Miura T, Brockman MA, Schneidewind A, Lobritz M, Pereyra F, Rathod A, Block BL, Brumme ZL, Brumme CJ, Baker B, Rothchild AC, Li B, Trocha A, Cutrell E, Frahm N, Brander C, Toth I, Arts EJ, Allen TM, Walker BD.

J Virol. 2009 Mar;83(6):2743-55. doi: 10.1128/JVI.02265-08. Epub 2008 Dec 30. Erratum in: J Virol. 2009 Jun;83(11):5961.

10.

HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1.

Miura T, Brockman MA, Brumme ZL, Brumme CJ, Pereyra F, Trocha A, Block BL, Schneidewind A, Allen TM, Heckerman D, Walker BD.

J Virol. 2009 Jan;83(1):140-9. doi: 10.1128/JVI.01471-08. Epub 2008 Oct 29.

11.

Telomerase activity of HIV-1-specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors.

Lichterfeld M, Mou D, Cung TD, Williams KL, Waring MT, Huang J, Pereyra F, Trocha A, Freeman GJ, Rosenberg ES, Walker BD, Yu XG.

Blood. 2008 Nov 1;112(9):3679-87. doi: 10.1182/blood-2008-01-135442. Epub 2008 Aug 26.

12.

Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes.

Miura T, Brockman MA, Brumme CJ, Brumme ZL, Carlson JM, Pereyra F, Trocha A, Addo MM, Block BL, Rothchild AC, Baker BM, Flynn T, Schneidewind A, Li B, Wang YE, Heckerman D, Allen TM, Walker BD.

J Virol. 2008 Sep;82(17):8422-30. doi: 10.1128/JVI.00535-08. Epub 2008 Jun 18.

13.

Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human immunodeficiency virus type 1 capsid.

Schneidewind A, Brockman MA, Sidney J, Wang YE, Chen H, Suscovich TJ, Li B, Adam RI, Allgaier RL, Mothé BR, Kuntzen T, Oniangue-Ndza C, Trocha A, Yu XG, Brander C, Sette A, Walker BD, Allen TM.

J Virol. 2008 Jun;82(11):5594-605. doi: 10.1128/JVI.02356-07. Epub 2008 Apr 2.

14.

Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.

Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, Baker B, Trocha A, Rosenberg R, Mackey E, Ueda P, Lu Z, Cohen D, Wrin T, Petropoulos CJ, Rosenberg ES, Walker BD.

J Infect Dis. 2008 Feb 15;197(4):563-71. doi: 10.1086/526786.

PMID:
18275276
15.

A viral CTL escape mutation leading to immunoglobulin-like transcript 4-mediated functional inhibition of myelomonocytic cells.

Lichterfeld M, Kavanagh DG, Williams KL, Moza B, Mui SK, Miura T, Sivamurthy R, Allgaier R, Pereyra F, Trocha A, Feeney M, Gandhi RT, Rosenberg ES, Altfeld M, Allen TM, Allen R, Walker BD, Sundberg EJ, Yu XG.

J Exp Med. 2007 Nov 26;204(12):2813-24. Epub 2007 Nov 19.

16.

Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors.

Wey SJ, Augustyniak ME, Cochran ED, Ellis JL, Fang X, Garvey DS, Janero DR, Letts LG, Martino AM, Melim TL, Murty MG, Richardson SK, Schroeder JD, Selig WM, Trocha AM, Wexler RS, Young DV, Zemtseva IS, Zifcak BM.

J Med Chem. 2007 Dec 13;50(25):6367-82. Epub 2007 Nov 10.

PMID:
17994684
17.

Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection.

Lichterfeld M, Yu XG, Mui SK, Williams KL, Trocha A, Brockman MA, Allgaier RL, Waring MT, Koibuchi T, Johnston MN, Cohen D, Allen TM, Rosenberg ES, Walker BD, Altfeld M.

J Virol. 2007 Apr;81(8):4199-214. Epub 2007 Feb 7.

18.

Nef interference with HIV-1-specific CTL antiviral activity is epitope specific.

Adnan S, Balamurugan A, Trocha A, Bennett MS, Ng HL, Ali A, Brander C, Yang OO.

Blood. 2006 Nov 15;108(10):3414-9. Epub 2006 Aug 1.

19.

Synthesis and anti-inflammatory activity of a series of N-substituted naproxen glycolamides: nitric oxide-donor naproxen prodrugs.

Ranatunge RR, Augustyniak ME, Dhawan V, Ellis JL, Garvey DS, Janero DR, Letts LG, Richardson SK, Shumway MJ, Trocha AM, Young DV, Zemtseva IS.

Bioorg Med Chem. 2006 Apr 15;14(8):2589-99. Epub 2005 Dec 13.

PMID:
16356728
20.

NMI-1182, a gastro-protective cyclo-oxygenase-inhibiting nitric oxide donor.

Ellis JL, Augustyniak ME, Cochran ED, Earl RA, Garvey DS, Gordon LJ, Janero DR, Khanapure SP, Letts LG, Melim TL, Murty MG, Schwalb DJ, Shumway MJ, Selig WM, Trocha AM, Young DV, Zemtseva IS.

Inflammopharmacology. 2005;12(5-6):521-34.

PMID:
16259719
21.

Limited sequence evolution within persistently targeted CD8 epitopes in chronic human immunodeficiency virus type 1 infection.

Koibuchi T, Allen TM, Lichterfeld M, Mui SK, O'Sullivan KM, Trocha A, Kalams SA, Johnson RP, Walker BD.

J Virol. 2005 Jul;79(13):8171-81.

22.

HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response.

Feeney ME, Tang Y, Pfafferott K, Roosevelt KA, Draenert R, Trocha A, Yu XG, Verrill C, Allen T, Moore C, Mallal S, Burchett S, McIntosh K, Pelton SI, St John MA, Hazra R, Klenerman P, Altfeld M, Walker BD, Goulder PJ.

J Immunol. 2005 Jun 15;174(12):7524-30.

23.

3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: synthesis and biological evaluation.

Khanapure SP, Augustyniak ME, Earl RA, Garvey DS, Letts LG, Martino AM, Murty MG, Schwalb DJ, Shumway MJ, Trocha AM, Young DV, Zemtseva IS, Janero DR.

J Med Chem. 2005 Jun 2;48(11):3930-4.

PMID:
15916445
24.

Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II.

SenGupta D, Norris PJ, Suscovich TJ, Hassan-Zahraee M, Moffett HF, Trocha A, Draenert R, Goulder PJ, Binder RJ, Levey DL, Walker BD, Srivastava PK, Brander C.

J Immunol. 2004 Aug 1;173(3):1987-93.

25.

Migration of antigen-specific T cells away from CXCR4-binding human immunodeficiency virus type 1 gp120.

Brainard DM, Tharp WG, Granado E, Miller N, Trocha AK, Ren XH, Conrad B, Terwilliger EF, Wyatt R, Walker BD, Poznansky MC.

J Virol. 2004 May;78(10):5184-93.

26.

Combination of paclitaxel and nitric oxide as a novel treatment for the reduction of restenosis.

Lin CE, Garvey DS, Janero DR, Letts LG, Marek P, Richardson SK, Serebryanik D, Shumway MJ, Tam SW, Trocha AM, Young DV.

J Med Chem. 2004 Apr 22;47(9):2276-82.

PMID:
15084126
27.

Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles.

Ranatunge RR, Augustyniak M, Bandarage UK, Earl RA, Ellis JL, Garvey DS, Janero DR, Letts LG, Martino AM, Murty MG, Richardson SK, Schroeder JD, Shumway MJ, Tam SW, Trocha AM, Young DV.

J Med Chem. 2004 Apr 22;47(9):2180-93.

PMID:
15084117
28.

Impacts of avidity and specificity on the antiviral efficiency of HIV-1-specific CTL.

Yang OO, Sarkis PT, Trocha A, Kalams SA, Johnson RP, Walker BD.

J Immunol. 2003 Oct 1;171(7):3718-24.

29.

Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses.

Draenert R, Altfeld M, Brander C, Basgoz N, Corcoran C, Wurcel AG, Stone DR, Kalams SA, Trocha A, Addo MM, Goulder PJ, Walker BD.

J Immunol Methods. 2003 Apr 1;275(1-2):19-29.

PMID:
12667667
30.

Evolution and transmission of stable CTL escape mutations in HIV infection.

Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, Addo MM, Rosenberg ES, Nguyen T, Allen R, Trocha A, Altfeld M, He S, Bunce M, Funkhouser R, Pelton SI, Burchett SK, McIntosh K, Korber BT, Walker BD.

Nature. 2001 Jul 19;412(6844):334-8.

PMID:
11460164
31.

Persistence of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte clones in a subject with rapid disease progression.

Islam SA, Hay CM, Hartman KE, He S, Shea AK, Trocha AK, Dynan MJ, Reshamwala N, Buchbinder SP, Basgoz NO, Kalams SA.

J Virol. 2001 May;75(10):4907-11.

32.

Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children.

Goulder PJ, Tang Y, Brander C, Betts MR, Altfeld M, Annamalai K, Trocha A, He S, Rosenberg ES, Ogg G, O'Callaghan CA, Kalams SA, McKinney RE Jr, Mayer K, Koup RA, Pelton SI, Burchett SK, McIntosh K, Walker BD.

J Exp Med. 2000 Dec 18;192(12):1819-32.

33.

Distinct trafficking pathways mediate Nef-induced and clathrin-dependent major histocompatibility complex class I down-regulation.

Le Gall S, Buseyne F, Trocha A, Walker BD, Heard JM, Schwartz O.

J Virol. 2000 Oct;74(19):9256-66.

34.

Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay.

Altfeld MA, Trocha A, Eldridge RL, Rosenberg ES, Phillips MN, Addo MM, Sekaly RP, Kalams SA, Burchett SA, McIntosh K, Walker BD, Goulder PJ.

J Virol. 2000 Sep;74(18):8541-9.

35.

Efficient processing of the immunodominant, HLA-A*0201-restricted human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitope despite multiple variations in the epitope flanking sequences.

Brander C, Yang OO, Jones NG, Lee Y, Goulder P, Johnson RP, Trocha A, Colbert D, Hay C, Buchbinder S, Bergmann CC, Zweerink HJ, Wolinsky S, Blattner WA, Kalams SA, Walker BD.

J Virol. 1999 Dec;73(12):10191-8.

36.

Effects of intensified antihypertensive treatment in diabetic nephropathy: mortality and morbidity results of a prospective controlled 10-year study.

Trocha AK, Schmidtke C, Didjurgeit U, Mühlhauser I, Bender R, Berger M, Sawicki PT.

J Hypertens. 1999 Oct;17(10):1497-503.

PMID:
10526912
38.

Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection.

Kalams SA, Buchbinder SP, Rosenberg ES, Billingsley JM, Colbert DS, Jones NG, Shea AK, Trocha AK, Walker BD.

J Virol. 1999 Aug;73(8):6715-20.

39.

Processing of HIV-1 envelope glycoprotein for class I-restricted recognition: dependence on TAP1/2 and mechanisms for cytosolic localization.

Ferris RL, Hall C, Sipsas NV, Safrit JT, Trocha A, Koup RA, Johnson RP, Siliciano RF.

J Immunol. 1999 Feb 1;162(3):1324-32.

40.

Detection of HIV-1-specific CTLs in the semen of HIV-infected individuals.

Quayle AJ, Coston WM, Trocha AK, Kalams SA, Mayer KH, Anderson DJ.

J Immunol. 1998 Oct 15;161(8):4406-10.

41.

Immune modulation of human B lymphocytes by gene transfer with recombinant Epstein-Barr virus amplicons.

Wang F, Seldin DC, Annis B, Trocha A, Johnson RP.

J Virol Methods. 1998 May;72(1):81-93.

PMID:
9672135
42.

Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection.

Brander C, Hartman KE, Trocha AK, Jones NG, Johnson RP, Korber B, Wentworth P, Buchbinder SP, Wolinsky S, Walker BD, Kalams SA.

J Clin Invest. 1998 Jun 1;101(11):2559-66.

43.
44.

Identification of type-specific cytotoxic T lymphocyte responses to homologous viral proteins in laboratory workers accidentally infected with HIV-1.

Sipsas NV, Kalams SA, Trocha A, He S, Blattner WA, Walker BD, Johnson RP.

J Clin Invest. 1997 Feb 15;99(4):752-62.

45.

Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes.

Yang OO, Kalams SA, Rosenzweig M, Trocha A, Jones N, Koziel M, Walker BD, Johnson RP.

J Virol. 1996 Sep;70(9):5799-806.

46.

Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load.

Harrer T, Harrer E, Kalams SA, Barbosa P, Trocha A, Johnson RP, Elbeik T, Feinberg MB, Buchbinder SP, Walker BD.

J Immunol. 1996 Apr 1;156(7):2616-23.

PMID:
8786327
47.
49.

Longitudinal analysis of T cell receptor (TCR) gene usage by human immunodeficiency virus 1 envelope-specific cytotoxic T lymphocyte clones reveals a limited TCR repertoire.

Kalams SA, Johnson RP, Trocha AK, Dynan MJ, Ngo HS, D'Aquila RT, Kurnick JT, Walker BD.

J Exp Med. 1994 Apr 1;179(4):1261-71.

50.

Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine.

Johnson RP, Hammond SA, Trocha A, Siliciano RF, Walker BD.

AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S73-5. No abstract available.

PMID:
7532425

Supplemental Content

Loading ...
Support Center